Zhu LR - Search Results

1

[Study for drug-resistance of epithelial ovarian cancer by serum protein profiling].

Zhang WY, Zhu LR, Zheng YH, Zhou L, Zhang JZ, Wu JH, Liao QP. Zhang WY, et al. Among authors: zhu lr. Zhonghua Yi Xue Za Zhi. 2009 May 19;89(19):1326-9. Zhonghua Yi Xue Za Zhi. 2009. PMID: 19615186 Chinese.

2

[Expression of topoisomerase III alpha in epithelial ovarian tumors of different types and relation between the expression of topoisomerase III alpha and the clinical pathology of tumor].

Zhang WY, Pan Y, Zhu LR, Zhang JZ, Zhang M, Feng K, Zhou L, Yu L, Zhang XM, Ng SW. Zhang WY, et al. Among authors: zhu lr. Zhonghua Yi Xue Za Zhi. 2005 Nov 9;85(42):2988-91. Zhonghua Yi Xue Za Zhi. 2005. PMID: 16324386 Chinese.

3

Proteiomic patterns for endometrial cancer using SELDI-TOF-MS.

Zhu LR, Zhang WY, Yu L, Zheng YH, Hu J, Liao QP. Zhu LR, et al. J Zhejiang Univ Sci B. 2008 Apr;9(4):286-90. doi: 10.1631/jzus.B0710589. J Zhejiang Univ Sci B. 2008. PMID: 18381802 Free PMC article.

4

[The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].

Dong L, Chang XH, Ye X, Zhu LR, Zhao Y, Tian L, Cheng HY, Li XP, Zhang H, Liao QP, Fu TY, Cheng YX, Cui H. Dong L, et al. Among authors: zhu lr. Zhonghua Fu Chan Ke Za Zhi. 2008 Dec;43(12):931-6. Zhonghua Fu Chan Ke Za Zhi. 2008. PMID: 19134334 Chinese.

5

Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma.

Chang X, Ye X, Dong L, Cheng H, Cheng Y, Zhu L, Liao Q, Zhao Y, Tian L, Fu T, Chen J, Cui H. Chang X, et al. Int J Gynecol Cancer. 2011 Jul;21(5):852-8. doi: 10.1097/IGC.0b013e31821a3726. Int J Gynecol Cancer. 2011. PMID: 21633297

6

[Clinical analysis for death in gynecological patients].

Hu J, Zhu LR, Liao QP. Hu J, et al. Among authors: zhu lr. Beijing Da Xue Xue Bao Yi Xue Ban. 2010 Apr 18;42(2):155-8. Beijing Da Xue Xue Bao Yi Xue Ban. 2010. PMID: 20396355 Free article. Chinese.

7

[Assessment of magnetic resonance imaging in preoperative staging of endometrial carcinoma].

Zhu LR, Zhang Y, Wang XY, Liao QP. Zhu LR, et al. Beijing Da Xue Xue Bao Yi Xue Ban. 2006 Jun 18;38(3):249-51. Beijing Da Xue Xue Bao Yi Xue Ban. 2006. PMID: 16778965 Free article. Chinese.

8

[Results of different postoperative adjuvant therapies for stage Ib-IIa cervical carcinoma with risk factors].

Wen HW, Huang WP, Liu TY, Ma K, Tao X, Zhu LR, Liao QP. Wen HW, et al. Among authors: zhu lr. Zhonghua Fu Chan Ke Za Zhi. 2013 Dec;48(12):920-4. Zhonghua Fu Chan Ke Za Zhi. 2013. PMID: 24495686 Chinese.

9

Establishment and verification of the nomogram that predicts the 3-year recurrence risk of epithelial ovarian carcinoma.

Hu J, Jiao X, Zhu L, Guo H, Wu Y. Hu J, et al. BMC Cancer. 2020 Sep 29;20(1):938. doi: 10.1186/s12885-020-07402-2. BMC Cancer. 2020. PMID: 32993522 Free PMC article.

10

Clinical outcomes of fertility-sparing treatments in young patients with epithelial ovarian carcinoma.

Hu J, Zhu LR, Liang ZQ, Meng YG, Guo HY, Qu PP, Ma CL, Xu CJ, Yuan BB. Hu J, et al. Among authors: zhu lr. J Zhejiang Univ Sci B. 2011 Oct;12(10):787-95. doi: 10.1631/jzus.B1100166. J Zhejiang Univ Sci B. 2011. PMID: 21960341 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

67 results

Search Page

Filters